Biggest News Aggregation in the World
📰 Phase News

Page 1492 - Phase News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Phase. Real-time updates on events, politics, business and more.

Tessa Therapeutics Announces Successful Dosing of First Patient Cohort in Phase I Allogeneic Cell Therapy Trial

(1) BEDMINSTER, N.J. and SINGAPORE, Feb. 10, 2021 /PRNewswire/ -- Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, today announced the successful completion of dosing of the first patient cohort (n=3) in a Phase I dose escalation study, evaluating the safety and efficacy of Tessas TT11X - Allogeneic CD30-CAR Epstein Barr Virus Specific T-cell (EBVST) therapy. The Phase 1 study b...
United States Baylor College Of Medicine Malcolm Brenner Carlos Ramos Allogeneic Vsts Ivand Horak

KGO ABC World News Tonight With David Muir February 10, 2021 01:45:00

Shipments. >> its an issue now of scarcity, its an issue of supply. >> reporter: the vaccination effort amidst an urgent race to stop the spread of the new, more contagious variants. the white house saying it has stepped up monitoring. the uk variant now reported in at least 39 states. david, the biden administration says it will begin sending vaccine supply directly to community health centers starting next week. and the phase one will focus on 250 of those centers, 1 million vaccines administe...
White House Vaccination Effort Joe Biden Vaccine Supply Community Health Centers 1 Million

Tryp Therapeutics Inc.: Tryp Therapeutics Plans Phase 2a Eating Disorder Clinical Trial with Dr. Jennifer Miller

(2) La Jolla, California--(Newsfile Corp. - February 8, 2021) - Tryp Therapeutics ( CSE: TRYP) ("Tryp"), a leading pharmaceutical company focused on identifying and developing clinical-stage compounds for diseases with high unmet medical needs, announces it has commenced a collaboration with Dr. Jennifer Miller of the University of Florida as the Principal Investigator for a clinical trial to treat the symptoms associated with eating disorders. Tryp and Dr. Miller have begun designing a Phase 2...
United States Jim Kuo Jennifer Miller California Newsfile Corp University Of Florida Principal Investigator

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Curis Doses First Patient In Phase 1 Study Of CA-4948

Curis Doses First Patient In Phase 1 Study Of CA-4948 WASHINGTON (dpa-AFX) - Curis Inc. (CRIS) said that the first patient has been dosed in its Phase 1 trial evaluating CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in combination with ibrutinib, a BTK inhibitor, in patients with relapsed or refractory (R/R) hematologic malignancies. The initial data are expected in the fourth quarter of 2021. According to the company, the Phase 1 trial is a two-part, multicenter, open-label, dose es...
United States Curis Inc ஒன்றுபட்டது மாநிலங்களில் கரிஸ் இன்க்

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks

KalVista Pharmaceuticals, Inc.: KalVista Pharmaceuticals Reports Positive Results for KVD900 Phase 2 Demonstrating Statistically and Clinically Significant Responses Across All Endpoints as an Oral On-Demand Treatment for HAE Attacks KVD900 Generally Safe and Well-Tolerated - Conference Call to Discuss Trial Results Today at 8:30 a.m. ET - KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small ...
United States Kathryn Morris Andrew Crockett Leah Monteiro Drug Administration Corporate Communications Investor Relations

Heat Biologics, Inc.: Heat Biologics Announces Positive Interim Survival Data from Ongoing HS-110 Phase 2 Non-Small Cell Lung Cancer Trial

Median overall survival of 24.6 months in previously treated checkpoint inhibitor naïve non-small cell lung cancer patients who received HS-110 in combination with nivolumab DURHAM, NC / ACCESSWIRE /
David Waldman Jeff Wolf Bristol Myers Squibb Heat Biologics Inc Heat Biologics Chief Executive Officer

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science